Indacaterol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Indacaterol
- Indacaterol: From Chronic Obstructive Airway Disease to Nephrogenic Syndrome of Inappropriate Antidiuresis
Indacaterol: From Chronic Obstructive Airway Disease to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Indacaterol is a long-acting β2-adrenergic receptor agonist (LABA) used in respiratory disease (COPD/asthma) based on the trial and mechanistic evidence in this pack; formal original-indication text could not be confirmed because the drug is currently unlicensed in the target market. The TxGNN model's top-ranked prediction is Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this pairing has 0 clinical trials and 0 publications supporting it, and the evidence pack's own mechanistic review flags it as a likely knowledge-graph false positive. Across all 10 top-ranked TxGNN predictions for this drug, only one ("bronchial disease," rank 7) has strong clinical evidence (L1) — but that signal simply reconfirms the drug's known LABA pharmacology rather than representing a novel repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed by local license data (0 authorizations on file); drug class evidence points to COPD/asthma (LABA) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on the mechanistic evidence embedded throughout this pack's clinical trial and rationale entries, indacaterol is a long-acting β2-adrenergic receptor agonist that produces bronchodilation via direct action on airway smooth muscle β2 receptors — the pharmacological basis for its established use in obstructive airway disease.
NSIAD, in contrast, is a hereditary disorder caused by gain-of-function mutations in the vasopressin V2 receptor, which drives renal water retention independent of any β2-adrenergic pathway. There is no known pharmacological, receptor-level, or physiological overlap between LABA activity and V2-receptor-mediated free water handling. The evidence pack's own repurposing rationale for this candidate explicitly characterizes it as a graph-association false positive rather than a genuine mechanistic hypothesis, and no clinical trials or literature exist to counter that assessment.
For context, of the 10 highest-ranked TxGNN predictions for indacaterol, nine (NSIAD, headache disorder, trigeminal autonomic cephalalgia, paratenonitis, calcific tendinitis, hypertrichosis, myositis, anaphylaxis, Ambras-type hypertrichosis) are flagged in the source rationale as lacking mechanistic plausibility or reflecting adverse-event signals mistaken for therapeutic ones. The tenth ("bronchial disease") is well supported (L1, multiple Phase 3 RCTs) but represents the drug's already-established LABA pharmacology, not a new indication. Taken together, this evidence pack does not currently surface a credible novel repurposing candidate for indacaterol.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No authorizations are on file — this product is currently not marketed in the target jurisdiction, and no license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. Note that key warnings, contraindications, and drug-drug interaction data are all currently unavailable (flagged as a Blocking data gap — DG001: TFDA-equivalent package insert warnings/contraindications not yet sourced), which by itself precludes a full safety assessment (S1 stage) for any indication of this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (NSIAD) has no mechanistic plausibility, no clinical trials, and no literature support, and is explicitly assessed as a likely false positive. The only well-evidenced prediction in this pack ("bronchial disease") does not constitute a new indication. No repurposing case currently exists that would justify advancing past the earliest evaluation stage.
To proceed, the following is needed:
- TFDA-equivalent package insert (warnings/contraindications) — currently blocking (DG001)
- Detailed mechanism of action data from DrugBank — currently high-severity gap (DG002)
- A genuine mechanistic or preclinical rationale linking β2-adrenergic signaling to V2-receptor-mediated antidiuresis, if this candidate is to be pursued further
- If pursuing the "bronchial disease" signal instead, reframe as label-extension/on-mechanism confirmation rather than repurposing, and source formal local regulatory indication text
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.